Greg Freiherr, Industry Consultant

Greg Freiherr has reported on developments in radiology since 1983. He runs the consulting service, The Freiherr Group.

Sponsored Content | Blog | Greg Freiherr, Industry Consultant | PET-CT | October 08, 2018

How Digital PET/CT Can Improve Clinical Care

Digital PET/CT, achieved using Vereos from Philips Healthcare, can spot even a small lesion (arrow). Image courtesy of Brian Gordon, M.D.

Digital PET/CT, achieved using Vereos from Philips Healthcare, can spot even a small lesion (arrow). Image courtesy of Brian Gordon, M.D.

PET/CT can be indispensible as a diagnostic and prognostic tool; in the assessment of patient response to therapy and cancer recurrence; even in the choice of therapy. And the significance of this hybrid imaging modality could grow in future years.

Digitalization is increasing the medical value of PET/CT, according to Brian Gordon, M.D., who interprets the majority of digital PET/CTs performed at the WellStar Kennestone Cancer Center in Marietta, Ga.

“An improved patient experience is the major advantage of digital PET/CT,” said Gordon, head of Nuclear Medicine for Quantum Radiology, a subspecialty radiology group that interprets images for the sprawling WellStar Health System.

The digital detector built into the Vereos PET/CT from Philips Healthcare improves sensitivity and, consequently, the detectability of small lesions. And it does so while reducing scan time.

“We have seen a significant decrease in scan time,” he said. “About a third of the scan time has been removed.”

 

Patient First

The result is an enhanced patient experience, according to Gordon. The Vereos replaced an analog PET/CT at the WellStar Kennestone Cancer Center in November 2017. Since then, PET/CT scan volume has reached as high as 18 patients per day.

Despite the high throughput, which ranges from this peak to about a dozen scans per day, scan accuracy is excellent, he said.

The WellStar Kennestone Cancer Center is one of the busiest PET/CT providers in the state of Georgia, he said. The digital detector has dropped scan times for whole body exams from 50 to 30 minutes and ones from the base of the skull to mid-thigh from 30 to 20 minutes.

The vast majority of scans at the center are oncologic. Many are ordered to evaluate suspicious lesions that were spotted initially on CTs or MRIs, but Vereos is also used extensively to monitor patient response to cancer therapy and to look for cancer recurrence.

Although shorter scan times have boosted throughput at the cancer center and improved the patient experience, accuracy is the top priority, Gordon said. The increased sensitivity of the digital detector improves image quality, while short scan times make the patient more comfortable and less prone to move. This reduces the likelihood of motion artifacts that can degrade images.

The short scans do not reduce image quality, Gordon emphasized. On the contrary, compared with analog PET/CT that operated before Vereos, he said, “we are able to detect activity in smaller lesions.”

The ability to detect very small lesions is critically important when PET/CT is applied in staging or monitoring. This is where the digital detector excels, according to Philips’ Director of Clinical Science for Nuclear Medicine Piotr Maniawski.

“Digital technology allows us to improve small lesion detectability,” said Maniawski who has worked in nuclear medicine for more than three decades, mostly at Philips Healthcare.

Digital PET/CT is well suited to find recurrent disease and characterize patient response to therapy, while providing the option of fast scans, he said.

 

Transition to Digital

The difference digitalization can make is apparent during tumor boards at the WellStar Kennestone Cancer Center. Vereos delivers digital PET images, which can be fused with ones from CT, Gordon said. These colorized, fused images “improve the discussion because the clinicians can see what I am talking about,” he said.

Clear communication is especially important when planning patient management in tough cases, when therapy choices are not straightforward, he said, as exemplified when deciding whether a lesion may be resectable or if radiation or chemotherapy should be administered first. “If you can localize exactly where (the lesion) is, you can make better decisions,” Gordon said.

The clinical benefits possible with the digital photon counting detector built into the Vereos PET/CT could become even more significant in the future, Maniawski said.

The clinical prospects of PET/CT are derived from the relative certainty possible with the digital detector, Maniawski said. But academic science advances cautiously.

Several collaborative projects between Philips and academic centers are underway using Vereos “to deliver clinical proof not only for competitive differentiation (digital versus analog) but also to push molecular imaging forward,” he said.

 

*Disclaimer:  Results from case studies are not predictive of results in other case studies. Results in other case studies may vary.

Editor's note: This is the first blog in a series of four on digital PET/CT.

 

Related Content:

SPECIAL SUPPLEMENT: Examining the Value of Digital PET/CT

 

Related Content

MRI of Nonferromagnetic Ballistics Suspended in Gelatin. 

MRI of Nonferromagnetic Ballistics Suspended in Gelatin. Scout (A), T1-weighted spin-echo (SE) (B), T2-weighted SE (C), T2-weighted gradient-recalled echo (GRE) (TR/TE, 500/10; D), and T2-weighted GRE (TR/TE, 700/30; E) MR images show jacket hollow point .45 automatic Colt pistol bullet (Corbon) (1), solid lead .45 Long Colt bullet (Winchester) (2), full metal jacket (FMJ) automatic Colt pistol bullet (Winchester) (3), 5.56-mm FMJ bullet (Federal Ammunition) (4), #7 lead shotgun pellet (Winchester) (5), and 5-mm lead air gun pellet (Sheridan) (6). On all sequences, metallic artifact is minimal. Although metallic artifact increases or blooms with increased TR/TE in GRE images (D and E), amount of surrounding distortion is still minimal.

News | Magnetic Resonance Imaging (MRI) | January 15, 2021
January 15, 2021 — 
Novel Coronavirus SARS-CoV-2 Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Credit: National Institute of Allergy and Infectious Diseases, NIH

Novel Coronavirus SARS-CoV-2 Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Image courtesy of  National Institute of Allergy and Infectious Diseases (NIH)

News | Coronavirus (COVID-19) | January 15, 2021
January 15, 2021 — In one of the first studies to examine the impact of the...
Multidisciplinary functionality supports high-capacity utilization and economic efficiency
News | Mobile C-Arms | January 14, 2021
January 14, 2021 — Siemens Healthineers has announced the Food and Drug Administration (FDA) clearance of the...
Use of telehealth jumped sharply during the first months of the coronavirus pandemic shutdown, with the approach being used more often for behavioral health services than for medical care, according to a new RAND Corporation study.

Getty Images

News | Teleradiology | January 13, 2021
January 13, 2021 — Use of telehealth jumped sha
The U.S. Food and Drug Administration released the agency's first Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD) Action Plan. This action plan describes a multi-pronged approach to advance the Agency's oversight of AI/ML-based medical software.
News | Artificial Intelligence | January 12, 2021
January 12, 2021 — The U.S.
Myocarditis among recovering COVID-19 athletes less common than previously reported

Getty Images

News | Cardiac Imaging | January 11, 2021
January 11, 2021 — In a letter published in the December issue of the American Heart Association's...
Jeff Elias, MD, is a neurosurgeon at UVA Health and a pioneer in the field of focused ultrasound.

Jeff Elias, MD, is a neurosurgeon at UVA Health and a pioneer in the field of focused ultrasound. Image courtesy of UVA Health

News | Focused Ultrasound Therapy | January 08, 2021
January 8, 2021 — A scalpel-free alternative to brain surgery has the potential to benefit people with...
The FDA is monitoring the potential impact of viral mutations, including an emerging variant from the United Kingdom known as the B.1.1.7 variant, on authorized SARS-CoV-2 molecular tests

Getty Images

News | Coronavirus (COVID-19) | January 08, 2021
January 8, 2021 — The U.S.
World-first techniques for predicting breast cancer risk from mammograms that were developed in Melbourne could revolutionise breast screening by allowing it to be tailored to women at minimal extra cost

Getty Images

News | Mammography | January 06, 2021
January 6, 2021 — World-first techniques for predicting breast cancer risk from...